EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

The Safety of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: Analyses from a Prospective, Single-Arm, Multicenter, 12-Week Observational Study

Ying Li, Lin Dang, Chengzhi Lv, Bingjiang Lin, Juan Tao, Nan Yu, Ya Deng, Huiping Wang, Xiaojing Kang, Hui Qin, Rong Chen, Jinnan Li und 3 weitere

Drug Safety · 2024

DOI: 10.1007/s40264-024-01427-3 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Drug Safety, 2024. Verfasst von Ying Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, 200443, China. Hauptthemen laut MEDLINE: Psoriasis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisAntibodies, Monoclonal, HumanizedHumansMaleFemaleMiddle AgedProspective StudiesAdultAgedChinaSeverity of Illness IndexDermatologic AgentsProduct Surveillance, PostmarketingEast Asian People

Substanzen

ixekizumabAntibodies, Monoclonal, HumanizedDermatologic Agents

Autor:innen und Institutionen

  • Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, 200443, China.
  • Department of Dermatology, Longgang Central Hospital of Shenzhen, Shenzhen, Guangdong, China.
  • Department of Dermatology, Dalian Skin Disease Hospital, Dalian , Liaoning, China.
  • Department of Dermatology, Ningbo First Hospital, Ningbo, Zhejiang, China.
  • Department of Dermatology, Wuhan Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Department of Dermatology, General Hospital of Ningxia Medical Hospital, Yinchuan, Ningxia, China.

Förderung

  • Eli Lilly and Company

Zitieren

APA

Li, Y., Dang, L., Lv, C., Lin, B., Tao, J., Yu, N., Deng, Y., Wang, H., Kang, X., Qin, H., Chen, R., Li, J., Liang, Y., Liang, Y., & Shi, Y. (2024). The Safety of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: Analyses from a Prospective, Single-Arm, Multicenter, 12-Week Observational Study. Drug Safety. https://doi.org/10.1007/s40264-024-01427-3

Vancouver

Li Y, Dang L, Lv C, Lin B, Tao J, Yu N, et al. The Safety of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: Analyses from a Prospective, Single-Arm, Multicenter, 12-Week Observational Study. Drug Safety. 2024. doi:10.1007/s40264-024-01427-3

BibTeX
@article{Li2024,
  author = {Li, Ying and Dang, Lin and Lv, Chengzhi and Lin, Bingjiang and Tao, Juan and Yu, Nan and Deng, Ya and Wang, Huiping and Kang, Xiaojing and Qin, Hui and Chen, Rong and Li, Jinnan and Liang, Yunsheng and Liang, Yanhua and Shi, Yuling},
  title = {The Safety of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: Analyses from a Prospective, Single-Arm, Multicenter, 12-Week Observational Study},
  journal = {Drug Safety},
  year = {2024},
  doi = {10.1007/s40264-024-01427-3}
}
Kostenlos starten →